TY - JOUR
T1 - CRISPRs for optimal targeting
T2 - Delivery of CRISPR components as DNA, RNA, and protein into cultured cells and single-cell embryos
AU - Kouranova, Evguenia
AU - Forbes, Kevin
AU - Zhao, Guojun
AU - Warren, Joe
AU - Bartels, Angela
AU - Wu, Yumei
AU - Cui, Xiaoxia
N1 - Publisher Copyright:
© Evguenia Kouranova, et al., 2016; Published by Mary Ann Liebert, Inc. 2016.
PY - 2016/6/1
Y1 - 2016/6/1
N2 - The rapid development of CRISPR technology greatly impacts the field of genetic engineering. The simplicity in design and generation of highly efficient CRISPR reagents allows more and more researchers to take on genome editing in different model systems in their own labs, even for those who found it daunting before. An active CRISPR complex contains a protein component (Cas9) and an RNA component (small guide RNA [sgRNA]), which can be delivered into cells in various formats. Cas9 can be introduced as a DNA expression plasmid, in vitro transcripts, or as a recombinant protein bound to the RNA portion in a ribonucleoprotein particle (RNP), whereas the sgRNA can be delivered either expressed as a DNA plasmid or as an in vitro transcript. Here we compared the different delivery methods in cultured cell lines as well as mouse and rat single-cell embryos and view the RNPs as the most convenient and efficient to use. We also report the detection of limited off-targeting in cells and embryos and discuss approaches to lower that chance. We hope that researchers new to CRISPR find our results helpful to their adaptation of the technology for optimal gene editing.
AB - The rapid development of CRISPR technology greatly impacts the field of genetic engineering. The simplicity in design and generation of highly efficient CRISPR reagents allows more and more researchers to take on genome editing in different model systems in their own labs, even for those who found it daunting before. An active CRISPR complex contains a protein component (Cas9) and an RNA component (small guide RNA [sgRNA]), which can be delivered into cells in various formats. Cas9 can be introduced as a DNA expression plasmid, in vitro transcripts, or as a recombinant protein bound to the RNA portion in a ribonucleoprotein particle (RNP), whereas the sgRNA can be delivered either expressed as a DNA plasmid or as an in vitro transcript. Here we compared the different delivery methods in cultured cell lines as well as mouse and rat single-cell embryos and view the RNPs as the most convenient and efficient to use. We also report the detection of limited off-targeting in cells and embryos and discuss approaches to lower that chance. We hope that researchers new to CRISPR find our results helpful to their adaptation of the technology for optimal gene editing.
UR - http://www.scopus.com/inward/record.url?scp=84975505451&partnerID=8YFLogxK
U2 - 10.1089/hum.2016.009
DO - 10.1089/hum.2016.009
M3 - Article
C2 - 27094534
AN - SCOPUS:84975505451
SN - 1043-0342
VL - 27
SP - 464
EP - 475
JO - Human Gene Therapy
JF - Human Gene Therapy
IS - 6
ER -